

Wanliang Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10881859/publications.pdf>

Version: 2024-02-01

59
papers

2,931
citations

201674

27
h-index

189892

50
g-index

74
all docs

74
docs citations

74
times ranked

3135
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyrazinamide Inhibits Trans-Translation in <i>Mycobacterium tuberculosis</i> . <i>Science</i> , 2011, 333, 1630-1632.	12.6	475
2	Genetic Basis of Virulence Attenuation Revealed by Comparative Genomic Analysis of <i>Mycobacterium tuberculosis</i> Strain H37Ra versus H37Rv. <i>PLoS ONE</i> , 2008, 3, e2375.	2.5	200
3	Mechanisms of Pyrazinamide Action and Resistance. <i>Microbiology Spectrum</i> , 2014, 2, 1-12.	3.0	178
4	Energy production genes <i>sucB</i> and <i>ubiF</i> are involved in persister survival and tolerance to multiple antibiotics and stresses in <i>Escherichia coli</i> . <i>FEMS Microbiology Letters</i> , 2010, 303, 33-40.	1.8	159
5	Mutations in <i>panD</i> encoding aspartate decarboxylase are associated with pyrazinamide resistance in <i>Mycobacterium tuberculosis</i> . <i>Emerging Microbes and Infections</i> , 2013, 2, 1-5.	6.5	136
6	Identification of novel mutations associated with clofazimine resistance in <i>Mycobacterium tuberculosis</i> : Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2507-2510.	3.0	125
7	Aspartate decarboxylase (PanD) as a new target of pyrazinamide in <i>Mycobacterium tuberculosis</i> . <i>Emerging Microbes and Infections</i> , 2014, 3, 1-8.	6.5	122
8	Identification of novel activity against <i>Borrelia burgdorferi</i> persisters using an FDA approved drug library. <i>Emerging Microbes and Infections</i> , 2014, 3, 1-8.	6.5	99
9	An Optimized SYBR Green I/PI Assay for Rapid Viability Assessment and Antibiotic Susceptibility Testing for <i>Borrelia burgdorferi</i> . <i>PLoS ONE</i> , 2014, 9, e111809.	2.5	92
10	Trans-translation mediates tolerance to multiple antibiotics and stresses in <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2477-2481.	3.0	67
11	An extracellular halophilic protease SptA from a halophilic archaeon <i>Natrinema</i> sp. J7: gene cloning, expression and characterization. <i>Extremophiles</i> , 2006, 10, 599-606.	2.3	65
12	Genetic Screen Reveals the Role of Purine Metabolism in <i>Staphylococcus aureus</i> Persistence to Rifampicin. <i>Antibiotics</i> , 2015, 4, 627-642.	3.7	64
13	PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1237-1242.	3.0	51
14	Disruption of Membrane by Colistin Kills Uropathogenic <i>Escherichia coli</i> Persisters and Enhances Killing of Other Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6867-6871.	3.2	50
15	A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro <i>Borrelia burgdorferi</i> Persisters from an FDA Drug Library. <i>Frontiers in Microbiology</i> , 2016, 7, 743.	3.5	49
16	<i>Mycobacterium tuberculosis</i> Mutations Associated with Reduced Susceptibility to Linezolid. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2542-2544.	3.2	49
17	Identification of novel mutations associated with cycloserine resistance in <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3272-3276.	3.0	46
18	Identification of Genes Involved in Bacteriostatic Antibiotic-Induced Persister Formation. <i>Frontiers in Microbiology</i> , 2018, 9, 413.	3.5	45

#	ARTICLE	IF	CITATIONS
19	Identification of Additional Anti-Persister Activity against <i>Borrelia burgdorferi</i> from an FDA Drug Library. <i>Antibiotics</i> , 2015, 4, 397-410.	3.7	43
20	Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm <i>Borrelia burgdorferi</i> . <i>Frontiers in Medicine</i> , 2017, 4, 169.	2.6	43
21	Identification of new compounds with high activity against stationary phase <i>Borrelia burgdorferi</i> from the NCI compound collection. <i>Emerging Microbes and Infections</i> , 2015, 4, 1-15.	6.5	42
22	Mutation in <i>clpC1</i> encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in <i>Mycobacterium tuberculosis</i> . <i>Emerging Microbes and Infections</i> , 2017, 6, 1-2.	6.5	41
23	Identification of Essential Oils with Strong Activity against Stationary Phase <i>Borrelia burgdorferi</i> . <i>Antibiotics</i> , 2018, 7, 89.	3.7	41
24	Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in <i>M. tuberculosis</i> . <i>Frontiers in Microbiology</i> , 2019, 10, 216.	3.5	37
25	The molecular basis of pyrazinamide activity on <i>Mycobacterium tuberculosis</i> PanD. <i>Nature Communications</i> , 2020, 11, 339.	12.8	37
26	Stationary phase persister/biofilm microcolony of <i>Borrelia burgdorferi</i> causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. <i>Discovery Medicine</i> , 2019, 27, 125-138.	0.5	36
27	Characterization of a novel plasmid from extremely halophilic Archaea: nucleotide sequence and function analysis. <i>FEMS Microbiology Letters</i> , 2003, 221, 53-57.	1.8	34
28	Persister mechanisms in <i>Borrelia burgdorferi</i> : implications for improved intervention. <i>Emerging Microbes and Infections</i> , 2015, 4, 1-3.	6.5	31
29	Eradication of Biofilm-Like Microcolony Structures of <i>Borrelia burgdorferi</i> by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. <i>Frontiers in Microbiology</i> , 2016, 7, 62.	3.5	30
30	Identification of Anti-Persister Activity against Uropathogenic <i>Escherichia coli</i> from a Clinical Drug Library. <i>Antibiotics</i> , 2015, 4, 179-187.	3.7	29
31	Glycerol Uptake Is Important for L-Form Formation and Persistence in <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2014, 9, e108325.	2.5	27
32	Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony <i>B. burgdorferi</i> Persists Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing. <i>Frontiers in Microbiology</i> , 2016, 7, 1744.	3.5	25
33	Identification of essential oils with activity against stationary phase <i>Staphylococcus aureus</i> . <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 99.	2.7	25
34	Single nucleotide polymorphisms in efflux pumps genes in extensively drug resistant <i>Mycobacterium tuberculosis</i> isolates from Pakistan. <i>Tuberculosis</i> , 2017, 107, 20-30.	1.9	24
35	A Rapid Growth-Independent Antibiotic Resistance Detection Test by SYBR Green/Propidium Iodide Viability Assay. <i>Frontiers in Medicine</i> , 2018, 5, 127.	2.6	24
36	Novel Mutations Associated with Clofazimine Resistance in <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23

#	ARTICLE	IF	CITATIONS
37	A Clinical Drug Library Screen Identifies Tosufloxacin as Being Highly Active against <i>Staphylococcus aureus</i> Persisters. <i>Antibiotics</i> , 2015, 4, 329-336.	3.7	21
38	Identification of Novel Mutations in LprG (<i>rv1411c</i>), <i>rv0521</i> , <i>rv3630</i> , <i>rv0010c</i> , <i>ppsC</i> , and <i>cyp128</i> Associated with Pyrazinoic Acid/Pyrazinamide Resistance in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
39	Introducing RpsA Point Mutations $\hat{I}^{\prime}438A$ and D123A into the Chromosome of <i>Mycobacterium tuberculosis</i> Confirms Their Role in Causing Resistance to Pyrazinamide. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
40	Identification of Agents Active against Methicillin-Resistant <i>Staphylococcus aureus</i> USA300 from a Clinical Compound Library. <i>Pathogens</i> , 2017, 6, 44.	2.8	15
41	Activity of Sulfa Drugs and Their Combinations against Stationary Phase <i>B. burgdorferi</i> In Vitro. <i>Antibiotics</i> , 2017, 6, 10.	3.7	15
42	Identification of FDA-Approved Drugs with Activity against Stationary Phase <i>Bartonella henselae</i> . <i>Antibiotics</i> , 2019, 8, 50.	3.7	15
43	Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of <i>Bartonella henselae</i> in vitro. <i>BMC Microbiology</i> , 2020, 20, 87.	3.3	15
44	Evaluation of mycobacterial virulence using rabbit skin liquefaction model. <i>Virulence</i> , 2010, 1, 156-163.	4.4	14
45	Conditions and mutations affecting <i>Staphylococcus aureus</i> L-form formation. <i>Microbiology (United Kingdom)</i> 151, 1078-1087. <small>1.84314 rgBT /Over 12</small>		
46	Evaluation of Disulfiram Drug Combinations and Identification of Other More Effective Combinations against Stationary Phase <i>Borrelia burgdorferi</i> . <i>Antibiotics</i> , 2020, 9, 542.	3.7	12
47	Essential Oils with High Activity against Stationary Phase <i>Bartonella henselae</i> . <i>Antibiotics</i> , 2019, 8, 246.	3.7	11
48	Identification of Essential Oils Including Garlic Oil and Black Pepper Oil with High Activity against <i>Babesia duncani</i> . <i>Pathogens</i> , 2020, 9, 466.	2.8	10
49	Mechanisms of Pyrazinamide Action and Resistance. , 0, , 479-491.		10
50	Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) in <i>Mycobacterium tuberculosis</i> by Competing with tmRNA. <i>Pathogens</i> , 2019, 8, 230.	2.8	9
51	Increased expression of efflux pump genes in extensively drug-resistant isolates of <i>Mycobacterium tuberculosis</i> . <i>International Journal of Mycobacteriology</i> , 2016, 5, S150.	0.6	8
52	Varying effects of common tuberculosis drugs on enhancing clofazimine activity <i>in vitro</i> . <i>Emerging Microbes and Infections</i> , 2017, 6, 1-3.	6.5	7
53	Molecular mechanisms of clofazimine resistance in <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2943-2944.	3.0	7
54	Infection with persister forms of <i>Staphylococcus aureus</i> causes a persistent skin infection with more severe lesions in mice: failure to clear the infection by the current standard of care treatment. <i>Discovery Medicine</i> , 2019, 28, 7-16.	0.5	6

#	ARTICLE	IF	CITATIONS
55	Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-3.	6.5	5
56	Activity of Pyrazinamide against <i>Mycobacterium tuberculosis</i> at Neutral pH in PZA-S1 Minimal Medium. <i>Antibiotics</i> , 2021, 10, 909.	3.7	5
57	Identification of essential oils with strong activity against stationary phase uropathogenic <i>Escherichia coli</i> . <i>Discovery Medicine</i> , 2019, 28, 179-188.	0.5	3
58	Identification and Ranking of Clinical Compounds with Activity Against Log-phase Growing Uropathogenic <i>Escherichia coli</i> . <i>Current Drug Discovery Technologies</i> , 2020, 17, 191-196.	1.2	2
59	Identification of a novel gene <i>argJ</i> involved in arginine biosynthesis critical for persister formation in <i>Staphylococcus aureus</i> . <i>Discovery Medicine</i> , 2020, 29, 65-77.	0.5	0